Table 4.
Clinical Trials Based on Human Pluripotent Stem Cells
| Sponsor | Disease(s) (as Indicated) | Study ID | Country |
|---|---|---|---|
| Clinical Trials Based on hESCs | |||
| Assistance Publique – Hôpitaux de Paris | ischemic heart disease | NCT02057900 | France |
| Astellas Pharma | Stargardt macular dystrophy | NCT01345006 | United States |
| Astellas Pharma | advanced dry AMD | NCT02463344 | United States |
| Astellas Pharma | AMD | NCT03178149 | not specified |
| Astellas Pharma | AMD | NCT01344993 | United States |
| Astellas Pharma | Stargardt macular dystrophy | NCT02941991 | UK |
| Astellas Pharma | Stargardt macular dystrophy | NCT01469832 | UK |
| Astellas Pharma | Stargardt macular dystrophy | NCT02445612 | United States |
| Astellas Pharma | macular degenerative disease | NCT03167203 | not specified |
| Asterias Biotherapeutics | spinal cord injury | NCT02302157 | United States |
| Asterias Biotherapeutics | spinal cord injury | NCT01217008 | United States |
| Cell Cure Neurosciences | AMD | NCT02286089 | Israel, United States |
| CHA Biotech | dry AMD | NCT01674829 | Korea |
| CHA Biotech | Stargardt macular dystrophy | NCT01625559 | Korea |
| Chinese Academy of Sciences | dry AMD | NCT03046407 | China |
| Chinese Academy of Sciences | nonexudative AMD | NCT02755428 | China |
| Chinese Academy of Sciences | Parkinson's disease | NCT03119636 | China |
| Chinese Academy of Sciences, Institute of Zoology | dry AMD | ChiCTR-OCB-15007054 | China |
| Chinese Academy of Sciences, Institute of Zoology | retinitis pigmentosa | ChiCTR-OCB-15007055 | China |
| Eye Institute of Xiamen University | severe ocular surface diseases | ChiCTR-OCB-15005968 | China |
| Federal University of São Paulo | AMD, Stargardt disease, exudative AMD | NCT02903576 | Brazil |
| Pfizer | AMD | NCT03102138 | UK |
| Pfizer | AMD | NCT01691261 | UK |
| Regenerative Patch Technologies | dry AMD | NCT02590692 | United States |
| Southwest Hospital, China | macular degeneration diseases, not specified | NCT02749734 | China |
| Viacyte | diabetes mellitus type 1 | NCT03162926 | Canada |
| Viacyte | diabetes mellitus type 1 | NCT02239354 | United States, Canada |
| Viacyte | diabetes mellitus type 1 | NCT02939118 | United States, Canada |
| Viacyte | diabetes mellitus type 1 with hypoglycemia | NCT03163511 | United States |
| Clinical Trials Based on hiPSCs | |||
| RIKEN | exudative AMD | UMIN000011929 (based on autologous iPSCs) | Japan |
| Cynata Therapeutics | graft-versus-host disease | NCT02923375 (based on allogenic iPSCs) | Australia, UK |
| Kobe City Medical Center General Hospital | neovascular AMD | UMIN000026003 (based on allogenic iPSCs) | Japan |
Follow-up studies among hPSC-based trials are highlighted with a blue background. Withdrawn studies were not included. Studies that only aim at the derivation of patient-specific hiPSC lines and therapeutic cells thereof (but not at the treatment of patients with these hiPSC-derived therapeutic cells) were not included either. iPSCs, induced pluripotent stem cells.